Sandoz partners with mAbxience to develop emicizumab biosimilar###
Sandoz signed a licensing, development, manufacturing, commercialisation deal with mAbxience for a proposed emicizumab biosimilar. Agreement gives Sandoz exclusive global commercialisation rights, excluding Argentina, Uruguay, Paraguay; mAbxience will handle development, manufacturing. Targets Hemlibra reference market